OBJECTIVES: To evaluate real-world patient characteristics and treatment regimens in patients with hemophilia A using recently approved rFVIII therapies in the US, based on specialty pharmacy dispensing records. METHODS:  A retrospective analysis was performed using a database composed of aggregate, de-identified US Specialty Pharmacy Provider (SPP) records from July 2014 through November 2016. Patients eligible for this analysis had received ≥1 shipment of a recently approved rFVIII factor therapy. Recently approved factor therapies were defined as therapies approved in 2014 or later, which includes: ELOCTATE, ADYNOVATE, ALFSTYA, NUWIQ, KOVALTRY, and NOVOEIGHT. Patients were categorized based on their age, regimen and prescribed dosing frequency. Analysis of prophylactic regimens included only ELOCTATE and ADYNOVATE because of the low number of patients on other therapies. RESULTS: A total of 1174 patients with hemophilia A of unknown severity were included in this analysis. Forty-three percent of patients were >18 years of age, 41% were 18-39, and 16% were >40; average weights were 39kg, 84kg, and 84kg, respectively. Most patients were treated with a prophylaxis regimen (88%) with the remaining being treated on-demand (12%). ELOCTATE (71% of patients) was the most frequently dispensed therapy followed by ADYNOVATE (17%), NOVOEIGHT (8%), KOVALTRY (2%), NUWIQ (2%), ALFSTYLA (0%). The most commonly prescribed prophylactic infusion frequency was twice weekly, representing 48% of patient records. Patients on ELOCTATE (37%) were more likely to have an infusion frequency longer than twice weekly than patients treated with ADYNOVATE (13%). CONCLUSIONS: Recently approved rFVIII therapies have been prescribed for a large number of patients with hemophilia A in the United States. ELOCATATE is the most frequently utilized of these rFVIII therapies based on SPP dispensing records. Patients prescribed ELOCTATE and ADYNOVATE achieved extended prophylactic infusion frequencies. Those on ELOCATE therapy were more likely to be prescribed an infusion frequency longer than twice weekly.